ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

ClinicalTrials.gov ID: NCT06624228

Public ClinicalTrials.gov record NCT06624228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Study identification

NCT ID
NCT06624228
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Biopharma SRL
Industry
Enrollment
684 participants

Conditions and interventions

Interventions

  • Bimekizumab Drug
  • Placebo Drug
  • Risankizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 20, 2024
Primary completion
Feb 5, 2026
Completion
May 25, 2026
Last update posted
Apr 12, 2026

2024 – 2026

United States locations

U.S. sites
34
U.S. states
16
U.S. cities
34
Facility City State ZIP Site status
Pa0016 50662 Gilbert Arizona 85297
Pa0016 50062 Glendale Arizona 85306
Pa0016 50058 Phoenix Arizona 85032
Pa0016 50131 Sun City Arizona 85351
Pa0016 50654 Covina California 91722
Pa0016 50663 San Diego California 92128
Pa0016 50672 Santa Monica California 90404
Pa0016 50630 Clearwater Florida 33765
Pa0016 50679 Cutler Bay Florida 33189
Pa0016 50685 Fort Lauderdale Florida 33309
Pa0016 50059 Ormond Beach Florida 32174
Pa0016 50324 Plantation Florida 33324
Pa0016 50678 Zephyrhills Florida 33542
Pa0016 50651 Skokie Illinois 60076
Pa0016 50650 Willowbrook Illinois 60527
Pa0016 50686 Hagerstown Maryland 21740
Pa0016 50665 Lansing Michigan 48910
Pa0016 50551 Saint Clair Shores Michigan 48081
Pa0016 50689 Eagan Minnesota 55123
Pa0016 50682 Kansas City Missouri 64111
Pa0016 50016 St Louis Missouri 63141
Pa0016 50653 Albuquerque New Mexico 87102
Pa0016 50666 Brooklyn New York 11201
Pa0016 50664 Middletown Ohio 45044
Pa0016 50680 Vandalia Ohio 45377
Pa0016 50652 Duncansville Pennsylvania 16635
Pa0016 50006 Wyomissing Pennsylvania 19610
Pa0016 50001 Jackson Tennessee 38305
Pa0016 50673 Fort Worth Texas 76109
Pa0016 50048 Katy Texas 77449
Pa0016 50657 Lubbock Texas 79424
Pa0016 50655 Tomball Texas 77375
Pa0016 50061 Spokane Valley Washington 99216
Pa0016 50674 Glendale Wisconsin 53217

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 93 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06624228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06624228 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →